|
US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
US6960662B2
(en)
*
|
2000-08-04 |
2005-11-01 |
Warner-Lambert Company |
Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
|
|
WO2003027110A2
(en)
*
|
2000-08-04 |
2003-04-03 |
Warner-Lambert Company |
Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido [2,3-d]pyrimidin-7-ones
|
|
ES2249574T3
(es)
*
|
2001-02-12 |
2006-04-01 |
F. Hoffmann-La Roche Ag |
Pirido-pirimidinas 6-sustituidas.
|
|
NZ527741A
(en)
*
|
2001-02-26 |
2005-02-25 |
Tanabe Seiyaku Co |
Pyridopyrimidine or naphthyridine derivative
|
|
EP1408985A4
(en)
*
|
2001-06-21 |
2006-03-22 |
Ariad Pharma Inc |
NEW PYRIDOPYRIMIDONE AND ITS USES
|
|
US20050154046A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Longgui Wang |
Methods of treating an inflammatory-related disease
|
|
BR122016021801B8
(pt)
|
2002-01-22 |
2021-05-25 |
Warner Lambert Co |
compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
|
|
ES2293064T3
(es)
*
|
2002-08-06 |
2008-03-16 |
F. Hoffmann-La Roche Ag |
6-alcoxi-pirido-pirimidinas como inhibidores de la p-38 map quinasa.
|
|
US7112676B2
(en)
|
2002-11-04 |
2006-09-26 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
|
AU2003288994A1
(en)
|
2002-12-10 |
2004-06-30 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compounds and medicinal use thereof
|
|
KR100864393B1
(ko)
|
2003-04-10 |
2008-10-20 |
에프. 호프만-라 로슈 아게 |
피리미도 화합물
|
|
DK1648889T3
(da)
*
|
2003-07-11 |
2009-01-05 |
Warner Lambert Co |
Isethionatsalt af en selektiv CDK4-inhibitor
|
|
EP2256106B1
(en)
|
2003-07-22 |
2015-05-06 |
Astex Therapeutics Limited |
3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
|
WO2005011654A2
(en)
*
|
2003-07-29 |
2005-02-10 |
Xenon Pharmaceuticals Inc. |
Pyridyl derivatives and their use as therapeutic agents
|
|
HRP20070132T3
(en)
*
|
2003-11-13 |
2007-05-31 |
F. Hoffmann - La Roche Ag |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
|
WO2005058341A2
(en)
*
|
2003-12-11 |
2005-06-30 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
DK1713806T3
(da)
*
|
2004-02-14 |
2013-08-05 |
Irm Llc |
Forbindelser og sammensætninger som proteinkinaseinhibitorer
|
|
JP2007523151A
(ja)
*
|
2004-02-18 |
2007-08-16 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
|
|
EP1740184A1
(en)
*
|
2004-03-30 |
2007-01-10 |
Pfizer Products Incorporated |
Combinations of signal transduction inhibitors
|
|
DK1761528T3
(da)
*
|
2004-06-11 |
2008-05-05 |
Japan Tobacco Inc |
5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidin-derivater og beslægtede forbindelser til behandling af cancer
|
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
|
CA2586761A1
(en)
|
2004-11-10 |
2006-05-18 |
Genzyme Corporation |
Methods of treating diabetes mellitus
|
|
US20060142312A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Inc |
C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
|
|
BRPI0606480A
(pt)
*
|
2005-01-21 |
2008-03-11 |
Astex Therapeutics Ltd |
compostos farmacêuticos
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
CN101146533A
(zh)
*
|
2005-01-21 |
2008-03-19 |
阿斯泰克斯治疗有限公司 |
吡唑激酶抑制剂和其它抗肿瘤剂的组合
|
|
US20090036435A1
(en)
*
|
2005-01-21 |
2009-02-05 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
JP5272408B2
(ja)
*
|
2005-02-25 |
2013-08-28 |
小野薬品工業株式会社 |
含窒素複素環化合物およびその医薬用途
|
|
PE20100741A1
(es)
*
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
|
|
MY145343A
(en)
*
|
2005-03-25 |
2012-01-31 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2006122150A1
(en)
|
2005-05-10 |
2006-11-16 |
Incyte Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
|
KR100734837B1
(ko)
*
|
2005-09-16 |
2007-07-03 |
한국전자통신연구원 |
다중 생체 인식 시스템 및 그 방법
|
|
WO2007036791A1
(en)
*
|
2005-09-28 |
2007-04-05 |
Ranbaxy Laboratories Limited |
Pyrido-pyridimidine derivatives useful as antiinflammatory agents
|
|
KR101538412B1
(ko)
*
|
2005-10-07 |
2015-07-22 |
엑셀리시스, 인코포레이티드 |
ＰＩ３Ｋα의 피리도피리미디논 억제제
|
|
JP5480503B2
(ja)
*
|
2005-10-07 |
2014-04-23 |
エクセリクシス， インク． |
ＰＩ３Ｋαのピリドピリミジノン型阻害剤
|
|
EP2026805A1
(en)
*
|
2006-05-08 |
2009-02-25 |
Astex Therapeutics Limited |
Pharmaceutical combinations of diazole derivatives for cancer treatment
|
|
EP2032134B1
(en)
|
2006-05-09 |
2015-06-24 |
Genzyme Corporation |
Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
|
|
RU2009108006A
(ru)
*
|
2006-09-08 |
2010-10-20 |
Пфайзер Продактс Инк. (Us) |
Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
|
|
KR101099926B1
(ko)
|
2006-09-15 |
2011-12-28 |
화이자 프로덕츠 인코포레이티드 |
피리도 (2,3-ｄ) 피리미디논 화합물 및 이의 ｐｉ3 억제제로서의 용도
|
|
AU2007311480A1
(en)
*
|
2006-10-16 |
2008-04-24 |
Forma Therapeutics, Inc. |
Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
|
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
|
WO2008150260A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Gpc Biotech, Inc. |
8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
|
|
WO2008055842A1
(en)
*
|
2006-11-09 |
2008-05-15 |
F. Hoffmann-La Roche Ag |
Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
US8912177B2
(en)
|
2007-10-05 |
2014-12-16 |
Genzyme Corporation |
Method of treating polycystic kidney diseases with ceramide derivatives
|
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
MX2010010975A
(es)
|
2008-04-07 |
2010-11-01 |
Amgen Inc |
Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
|
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
|
ES2524266T3
(es)
|
2008-07-08 |
2014-12-04 |
Incyte Corporation |
1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
|
|
US8389517B2
(en)
|
2008-07-28 |
2013-03-05 |
Genzyme Corporation |
Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
|
|
UA103628C2
(en)
*
|
2008-08-22 |
2013-11-11 |
Новартис Аг |
Pyrrolopyrimidine compounds and use thereof
|
|
CA2738925A1
(en)
*
|
2008-10-01 |
2010-04-08 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
|
|
EP2341906A4
(en)
|
2008-10-01 |
2012-06-13 |
Univ North Carolina |
HEMATOPOIETIC PROTECTION AGAINST IONIZATION RADIATION USING SELF-ACTIVE CYCLINE-DEPENDENT KINASE-4/6-HEMMER
|
|
EP3078373A1
(en)
*
|
2008-10-03 |
2016-10-12 |
Genzyme Corporation |
2-acylaminopropanol-type glucosylceramide synthase inhibitor
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
SG173178A1
(en)
|
2009-04-03 |
2011-09-29 |
Hoffmann La Roche |
Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
|
|
EP3406260B1
(en)
|
2009-05-13 |
2020-09-23 |
The University of North Carolina at Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
WO2011025006A1
(ja)
*
|
2009-08-31 |
2011-03-03 |
日本ケミファ株式会社 |
Ｇｐｒ１１９作動薬
|
|
EA201270498A1
(ru)
*
|
2009-10-09 |
2012-11-30 |
Афраксис, Инк. |
8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения заболеваний цнс
|
|
NZ629615A
(en)
|
2009-11-06 |
2016-01-29 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
US8889696B2
(en)
|
2009-12-18 |
2014-11-18 |
Temple University—Of the Commonwealth System of Higher Education |
Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
|
|
PH12012501361A1
(en)
|
2009-12-31 |
2012-10-22 |
Centro Nac De Investigaciones Oncologicas Cnio |
Tricyclic compounds for use as kinase inhibitors
|
|
MX2012011912A
(es)
|
2010-04-13 |
2012-11-16 |
Novartis Ag |
Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
|
|
TWI619713B
(zh)
|
2010-04-21 |
2018-04-01 |
普雷辛肯公司 |
用於激酶調節的化合物和方法及其適應症
|
|
EP2580217A4
(en)
*
|
2010-06-10 |
2014-06-18 |
Afraxis Holdings Inc |
6- (ETHYNYL-) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
|
|
EP3399026B1
(en)
|
2010-06-14 |
2024-06-26 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
AU2011286282B2
(en)
|
2010-08-05 |
2014-08-21 |
Temple University - Of The Commonwealth System Of Higher Education |
2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof
|
|
EP3381920B1
(en)
|
2010-10-25 |
2019-03-27 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
US9808461B2
(en)
|
2010-11-17 |
2017-11-07 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
|
PT2672967T
(pt)
|
2011-02-07 |
2018-12-07 |
Plexxikon Inc |
Compostos e métodos de modulação da quinase e suas indicações
|
|
KR20160035613A
(ko)
*
|
2011-03-23 |
2016-03-31 |
암젠 인크 |
Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
|
|
AU2012262489A1
(en)
|
2011-05-27 |
2013-04-04 |
Icahn School Of Medicine At Mount Sinai |
Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
|
|
EP2834237B1
(en)
*
|
2012-03-14 |
2018-06-06 |
Lupin Limited |
Heterocyclyl compounds as mek inhibitors
|
|
CA2868966C
(en)
|
2012-03-29 |
2021-01-26 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
BR112014030812B1
(pt)
|
2012-06-13 |
2022-11-08 |
Incyte Holdings Corporation |
Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr
|
|
PT2872491T
(pt)
|
2012-07-11 |
2021-08-05 |
Blueprint Medicines Corp |
Inibidores do recetor do fator de crescimento de fibroblastos
|
|
HK1213044A1
(zh)
|
2012-08-03 |
2016-06-24 |
Foundation Medicine, Inc. |
人乳头瘤病毒作为肿瘤预後的预测因子
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
MX361499B
(es)
|
2012-08-17 |
2018-12-06 |
Concert Pharmaceuticals Inc |
Baricitinib deuterado.
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
BR112015019508A8
(pt)
*
|
2013-02-21 |
2019-11-19 |
Pfizer |
formas sólidas de um inibidor de cdk4/6 seletivo
|
|
CA2906157C
(en)
|
2013-03-15 |
2022-05-17 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
WO2014144847A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
WO2014150925A2
(en)
|
2013-03-15 |
2014-09-25 |
Concert Pharmaceuticals, Inc. |
Deuterated palbociclib
|
|
SI2986610T1
(en)
|
2013-04-19 |
2018-04-30 |
Incyte Holdings Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2014183520A1
(zh)
*
|
2013-05-17 |
2014-11-20 |
上海恒瑞医药有限公司 |
吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
KR102405452B1
(ko)
|
2013-10-25 |
2022-06-03 |
블루프린트 메디신즈 코포레이션 |
섬유아세포 성장 인자 수용체의 억제
|
|
WO2015095840A1
(en)
*
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of cdk and erk inhibitors
|
|
US9796701B2
(en)
|
2013-12-31 |
2017-10-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
|
WO2015161287A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of normal cells during chemotherapy
|
|
EP3148532B1
(en)
|
2014-05-28 |
2021-03-03 |
Piramal Enterprises Limited |
Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
|
|
SG10202004716RA
(en)
|
2014-07-24 |
2020-06-29 |
Beta Pharma Inc |
2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
|
|
CA2954189A1
(en)
*
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
|
US20170217962A1
(en)
*
|
2014-07-31 |
2017-08-03 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
|
TW201618773A
(zh)
*
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
|
|
EP3180007A1
(en)
*
|
2014-08-14 |
2017-06-21 |
Sun Pharmaceutical Industries Ltd |
Crystalline forms of palbociclib
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
CN105111201B
(zh)
*
|
2014-10-16 |
2017-01-11 |
上海页岩科技有限公司 |
5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
|
CN105616418A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
|
JP6951973B2
(ja)
|
2014-11-12 |
2021-10-20 |
シージェン インコーポレイテッド |
グリカン相互作用化合物及び使用方法
|
|
CN104496983B
(zh)
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
|
CN104447743B
(zh)
*
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
|
EP3251672B1
(en)
|
2014-12-31 |
2023-02-01 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical composition comprising dabigatran etexilate and preparation method therefor
|
|
CN105732615B
(zh)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk激酶抑制剂
|
|
CN104610254B
(zh)
*
|
2015-01-26 |
2017-02-01 |
新发药业有限公司 |
一种帕博赛布的低成本制备方法
|
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
|
TWI690533B
(zh)
|
2015-02-12 |
2020-04-11 |
南北兄弟藥業投資有限公司 |
Ｃｄｋ類小分子抑制劑的化合物及其用途
|
|
MX388991B
(es)
|
2015-02-20 |
2025-03-20 |
Incyte Corp |
Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr)
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
|
CN106795159B
(zh)
*
|
2015-04-22 |
2018-12-28 |
江苏恒瑞医药股份有限公司 |
一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
|
|
TWI696617B
(zh)
*
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
|
DK3305785T3
(da)
*
|
2015-05-29 |
2021-10-11 |
Teijin Pharma Ltd |
Pyrido[3,4-d]pyrimidinderivat og farmaceutisk acceptabelt salt deraf
|
|
HUE047477T2
(hu)
|
2015-06-04 |
2020-04-28 |
Pfizer |
Palbociclib szilárd dózisformái
|
|
CN104892604B
(zh)
*
|
2015-06-19 |
2016-08-24 |
北京康立生医药技术开发有限公司 |
一种cdk4抑制剂的合成方法
|
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
|
SI3331881T1
(sl)
*
|
2015-08-05 |
2019-08-30 |
Ratiopharm Gmbh |
Nova kristalna oblika in adukti palbocikliba in matanojske kisline
|
|
CN105085517B
(zh)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
|
CN105130986B
(zh)
*
|
2015-09-30 |
2017-07-18 |
广州科擎新药开发有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其应用
|
|
HU230962B1
(hu)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Palbociclib sók
|
|
CN106632311B
(zh)
|
2015-11-02 |
2021-05-18 |
上海科胜药物研发有限公司 |
一种帕博西尼晶型a和晶型b的制备方法
|
|
MX2018005061A
(es)
|
2015-11-12 |
2019-02-28 |
Siamab Therapeutics Inc |
Compuestos de interacción con glicanos y métodos de uso.
|
|
CN105418603A
(zh)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
一种高纯度帕布昔利布及其反应中间体的制备方法
|
|
CN106810536A
(zh)
|
2015-11-30 |
2017-06-09 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
|
CN108699055B
(zh)
*
|
2015-12-13 |
2020-10-23 |
杭州英创医药科技有限公司 |
用作抗癌药物的杂环化合物
|
|
CN105418609B
(zh)
*
|
2015-12-31 |
2017-06-23 |
山东大学 |
4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
|
|
WO2017114512A1
(zh)
|
2015-12-31 |
2017-07-06 |
上海医药集团股份有限公司 |
含氮稠杂环化合物、制备方法、中间体、组合物和应用
|
|
CN106967061A
(zh)
*
|
2016-01-13 |
2017-07-21 |
常州方楠医药技术有限公司 |
帕博西林的盐、晶型及其制备方法
|
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
|
CN107266421B
(zh)
*
|
2016-04-08 |
2020-12-04 |
正大天晴药业集团股份有限公司 |
取代的苯并咪唑类衍生物
|
|
CN107286180B
(zh)
*
|
2016-04-11 |
2019-07-02 |
上海勋和医药科技有限公司 |
杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
|
|
CA3018434A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
CN106336411B
(zh)
*
|
2016-04-27 |
2018-03-06 |
上海医药集团股份有限公司 |
Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
|
|
CN105949189B
(zh)
*
|
2016-06-05 |
2017-09-22 |
童明琼 |
一种用于治疗乳腺癌的帕博西尼的制备方法
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
JP2019520379A
(ja)
|
2016-07-01 |
2019-07-18 |
ジー１ セラピューティクス， インコーポレイテッド |
ピリミジン系の抗増殖剤
|
|
WO2018007927A1
(en)
|
2016-07-04 |
2018-01-11 |
Dr. Reddy's Laboratories Limited |
Process for preparation of palbociclib
|
|
WO2018009735A1
(en)
|
2016-07-07 |
2018-01-11 |
Plantex Ltd. |
Solid state forms of palbociclib dimesylate
|
|
BR112019002610A2
(pt)
*
|
2016-08-15 |
2019-07-02 |
Pfizer |
piridopirimidinonas inibidoras de cdk2/4/6
|
|
JP7190425B2
(ja)
|
2016-08-23 |
2022-12-15 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝細胞癌の治療のための併用療法
|
|
CN110022900A
(zh)
|
2016-09-08 |
2019-07-16 |
蓝图药品公司 |
成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
|
|
US10710999B2
(en)
|
2016-10-07 |
2020-07-14 |
Mylan Laboratories Limited |
Polymorph of an intermediate for palbociclib synthesis
|
|
CA3040815C
(en)
|
2016-10-20 |
2021-07-20 |
Steven Martin Evans |
Anti-proliferative agents for treating pah
|
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
|
CN106565707B
(zh)
*
|
2016-11-03 |
2019-01-04 |
杭州科巢生物科技有限公司 |
帕博西尼新合成方法
|
|
EP3538148A1
(en)
|
2016-11-08 |
2019-09-18 |
Dana-Farber Cancer Institute |
Compositions and methods of modulating anti-tumor immunity
|
|
EP3541389A1
(en)
|
2016-11-16 |
2019-09-25 |
Pfizer Inc |
Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
SI3546458T1
(sl)
|
2016-11-28 |
2021-03-31 |
Teijin Pharma Limited |
Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka
|
|
HUE057706T2
(hu)
*
|
2016-11-28 |
2022-05-28 |
Teijin Pharma Ltd |
Pirido[3,4-d]pirimiden-származék vagy szolvátja kristálya
|
|
IL267299B
(en)
|
2016-12-16 |
2022-09-01 |
Cstone Pharmaceuticals |
Cdk4/6 inhibitor
|
|
TWI823845B
(zh)
|
2017-01-06 |
2023-12-01 |
美商G1治療公司 |
用於治療癌症的組合療法
|
|
CN108191857B
(zh)
*
|
2017-01-24 |
2020-10-23 |
晟科药业（江苏）有限公司 |
6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
|
|
US10729692B2
(en)
*
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
|
AU2018226824A1
(en)
|
2017-03-03 |
2019-09-19 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
US11192890B2
(en)
*
|
2017-03-03 |
2021-12-07 |
Auckland Uniservices Limited |
FGFR kinase inhibitors and pharmaceutical uses
|
|
RU2764724C2
(ru)
|
2017-03-16 |
2022-01-19 |
ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. |
Комбинированная терапия для лечения рака молочной железы
|
|
CN108658854A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种生物碱化合物及其制备方法和作为海洋防污剂的应用
|
|
CN108658855A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种含氮双环化合物及其制备方法和用途
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
TW201904577A
(zh)
|
2017-06-16 |
2019-02-01 |
美商貝達醫藥公司 |
N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
|
|
NZ759691A
(en)
|
2017-06-29 |
2023-05-26 |
G1 Therapeutics Inc |
Morphic forms of git38 and methods of manufacture thereof
|
|
EA036060B1
(ru)
*
|
2017-07-17 |
2020-09-21 |
Пфайзер Инк. |
Пиридопиримидиноновые ингибиторы cdk2/4/6
|
|
EP3658119A1
(en)
|
2017-07-28 |
2020-06-03 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
CN109384767B
(zh)
*
|
2017-08-08 |
2020-05-05 |
江苏恒瑞医药股份有限公司 |
一种吡啶并嘧啶类衍生物的制备方法及其中间体
|
|
CN111433375B
(zh)
|
2017-08-31 |
2024-07-30 |
诺华股份有限公司 |
选择针对癌症患者的治疗的方法
|
|
CN107488175A
(zh)
*
|
2017-09-04 |
2017-12-19 |
上海微巨实业有限公司 |
一种帕博西林关键中间体的制备方法
|
|
EP3695408A4
(en)
|
2017-10-02 |
2021-12-15 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
BR112020012635A2
(pt)
|
2017-12-22 |
2020-12-01 |
Ravenna Pharmaceuticals, Inc. |
derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase
|
|
CN108586452A
(zh)
*
|
2018-01-12 |
2018-09-28 |
重庆市碚圣医药科技股份有限公司 |
一种帕博西尼中间体的合成方法
|
|
TW201940166A
(zh)
|
2018-01-29 |
2019-10-16 |
美商貝達醫藥公司 |
作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途
|
|
CN108218861B
(zh)
*
|
2018-02-05 |
2019-07-23 |
黑龙江中医药大学 |
一种预防和治疗糖尿病的药物及其制备方法
|
|
JP7348665B2
(ja)
|
2018-02-06 |
2023-09-21 |
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ |
選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体
|
|
JP2021514975A
(ja)
|
2018-02-27 |
2021-06-17 |
ファイザー・インク |
サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
|
|
PE20251291A1
(es)
|
2018-02-27 |
2025-05-14 |
Incyte Corp |
Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
WO2019213544A2
(en)
|
2018-05-04 |
2019-11-07 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
|
US11911383B2
(en)
|
2018-05-14 |
2024-02-27 |
Pfizer Inc. |
Oral solution formulation
|
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
|
WO2019224194A1
(en)
|
2018-05-24 |
2019-11-28 |
Synthon B.V. |
A process for making palbociclib
|
|
GEP20237548B
(en)
|
2018-07-05 |
2023-10-10 |
Incyte Corp |
Fused pyrazine derivatives as a2a /a2b inhibitors
|
|
EP3826622A1
(en)
|
2018-07-23 |
2021-06-02 |
F. Hoffmann-La Roche AG |
Methods of treating cancer with pi3k inhibitor, gdc-0077
|
|
SG11202101807SA
(en)
|
2018-08-24 |
2021-03-30 |
G1 Therapeutics Inc |
Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
|
|
JP6952747B2
(ja)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
|
|
CN112839642A
(zh)
|
2018-10-08 |
2021-05-25 |
豪夫迈·罗氏有限公司 |
用PI3Kα抑制剂和二甲双胍治疗癌症的方法
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
CN113166148B
(zh)
*
|
2018-12-07 |
2024-04-12 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
|
KR20210107069A
(ko)
|
2018-12-21 |
2021-08-31 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 키나아제 저해제의 조합
|
|
EP3902801A4
(en)
*
|
2018-12-28 |
2022-12-14 |
SPV Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
US20230065740A1
(en)
|
2018-12-28 |
2023-03-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020157709A1
(en)
|
2019-02-01 |
2020-08-06 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
CN114040764A
(zh)
|
2019-02-15 |
2022-02-11 |
因赛特公司 |
细胞周期素依赖性激酶2生物标记物及其用途
|
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
|
CA3141531A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
JP2022533833A
(ja)
|
2019-05-24 |
2022-07-26 |
ファイザー・インク |
Ｃｄｋ阻害剤を使用した組合せ療法
|
|
CN112010844B
(zh)
*
|
2019-05-31 |
2023-07-25 |
中国药科大学 |
N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
WO2020253808A1
(zh)
*
|
2019-06-20 |
2020-12-24 |
江苏恒瑞医药股份有限公司 |
一种药物组合物以及其制备方法
|
|
CN110143948B
(zh)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
Cdk4/6抑制剂、其药物组合物、制备方法及应用
|
|
WO2021007146A1
(en)
|
2019-07-07 |
2021-01-14 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MX2022001133A
(es)
|
2019-08-01 |
2022-04-25 |
Incyte Corp |
Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
|
|
TW202115024A
(zh)
|
2019-08-14 |
2021-04-16 |
美商英塞特公司 |
作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
|
|
WO2021041348A1
(en)
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
KR20220099970A
(ko)
|
2019-10-11 |
2022-07-14 |
인사이트 코포레이션 |
Cdk2 억제제로서의 이환식 아민
|
|
PH12022550892A1
(en)
|
2019-10-14 |
2023-05-03 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN112759589B
(zh)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
嘧啶并吡啶酮类化合物及其应用
|
|
CN114901659A
(zh)
|
2019-11-26 |
2022-08-12 |
施万生物制药研发Ip有限责任公司 |
作为jak抑制剂的稠合嘧啶吡啶酮化合物
|
|
CA3156205A1
(en)
|
2019-12-03 |
2021-06-10 |
Jennifer O'hara Lauchle |
Combination therapies for treatment of breast cancer
|
|
JP2023505257A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7657222B2
(ja)
*
|
2019-12-16 |
2025-04-04 |
ルネラ・バイオテック・インコーポレーテッド |
選択的ｃｄｋ４／６阻害剤のがん治療薬
|
|
MX2022007487A
(es)
|
2019-12-16 |
2022-08-04 |
Lunella Biotech Inc |
Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US20230117684A1
(en)
|
2020-03-05 |
2023-04-20 |
Pfizer Inc. |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
|
EP4114401A1
(en)
|
2020-03-06 |
2023-01-11 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
|
JP7549032B2
(ja)
*
|
2020-03-13 |
2024-09-10 |
プロセネスター エルエルシー |
ＣＤＫ阻害剤としてのピリド［２，３－ｄ］ピリミジン－７（８Ｈ）－オン
|
|
US20230118053A1
(en)
*
|
2020-03-27 |
2023-04-20 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
|
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
|
|
AU2021254794A1
(en)
|
2020-04-16 |
2022-12-15 |
Incyte Corporation |
Fused tricyclic KRAS inhibitors
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
WO2021236650A1
(en)
|
2020-05-19 |
2021-11-25 |
G1 Therapeutics, Inc. |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
|
EP4157847A4
(en)
*
|
2020-05-28 |
2024-06-19 |
University of Washington |
Drug-like molecules and methods for the therapeutic targeting of viral rna structures
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
CN113880809B
(zh)
|
2020-07-03 |
2022-10-18 |
盛世泰科生物医药技术(苏州)有限公司 |
一种嘧啶类衍生物及其制备方法和应用
|
|
JP2022019654A
(ja)
|
2020-07-15 |
2022-01-27 |
ファイザー・インク |
がん処置のためのｋａｔ６阻害剤方法および組合せ
|
|
US20230321042A1
(en)
|
2020-07-20 |
2023-10-12 |
Pfizer Inc. |
Combination therapy
|
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
|
WO2022063119A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
南京济群医药科技股份有限公司 |
一种羟乙磺酸哌柏西利的组合物及药物
|
|
CN114306245A
(zh)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
无定形固体分散体的药物组合物及其制备方法
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
|
CN112569361B
(zh)
*
|
2020-12-30 |
2023-01-10 |
扬子江药业集团上海海尼药业有限公司 |
一种哌柏西利干混悬组合物及其制备方法
|
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
JP2024513575A
(ja)
|
2021-04-12 |
2024-03-26 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
|
|
US20240287065A1
(en)
*
|
2021-06-09 |
2024-08-29 |
Tyk Medicines (Zhengzhou) , Inc. |
Compound as cdk kinase inhibitor and use thereof
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
WO2022261160A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
EP4367117A1
(en)
|
2021-07-07 |
2024-05-15 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
JP2024529347A
(ja)
|
2021-07-14 |
2024-08-06 |
インサイト・コーポレイション |
Ｋｒａｓの阻害剤としての三環式化合物
|
|
AU2022320615B2
(en)
|
2021-07-26 |
2025-08-21 |
Celcuity Inc. |
1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
|
|
US20230174555A1
(en)
|
2021-08-31 |
2023-06-08 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
CN113683612B
(zh)
*
|
2021-09-07 |
2022-06-17 |
山东铂源药业股份有限公司 |
一种帕布昔利布的制备方法
|
|
WO2023040914A1
(zh)
*
|
2021-09-14 |
2023-03-23 |
甘李药业股份有限公司 |
一种cdk4/6抑制剂的医药用途
|
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
|
CA3234375A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
MX2024004444A
(es)
|
2021-10-14 |
2024-05-08 |
Incyte Corp |
Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
|
|
TW202320792A
(zh)
|
2021-11-22 |
2023-06-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
|
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
|
MX2024007015A
(es)
|
2021-12-10 |
2024-06-19 |
Lilly Co Eli |
Inhibidor de cdk4 y 6 en combinacion con fulvestrant para el tratamiento del cancer de mama avanzado o metastasico con receptor hormonal positivo y receptor 2 del factor de crecimiento epidermico humano negativo en pacientes tratados anteriormente con un inhibidor de cdk4 y 6.
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
|
CN118660889A
(zh)
|
2021-12-22 |
2024-09-17 |
因赛特公司 |
Fgfr抑制剂的盐和固体形式以及其制备方法
|
|
WO2023116884A1
(en)
|
2021-12-24 |
2023-06-29 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
|
KR20250004643A
(ko)
|
2022-03-07 |
2025-01-08 |
인사이트 코포레이션 |
Cdk2 억제제의 고체 형태, 염 및 제조 방법
|
|
HU231594B1
(hu)
*
|
2022-05-10 |
2025-03-28 |
Egis Gyógyszergyár Zrt. |
Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
|
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
|
EP4302755B1
(en)
|
2022-07-07 |
2025-08-20 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
|
WO2024015731A1
(en)
|
2022-07-11 |
2024-01-18 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
CN117430597A
(zh)
*
|
2022-07-14 |
2024-01-23 |
浙江同源康医药股份有限公司 |
用作cdk4激酶抑制剂的化合物及其应用
|
|
EP4561571A1
(en)
|
2022-07-29 |
2025-06-04 |
Pfizer Inc. |
Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
|
|
WO2024049926A1
(en)
|
2022-08-31 |
2024-03-07 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
|
CN120456897A
(zh)
|
2022-11-02 |
2025-08-08 |
佩特拉制药公司 |
用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
|
|
CN120187416A
(zh)
|
2022-11-11 |
2025-06-20 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的组合疗法
|
|
TW202440571A
(zh)
*
|
2022-12-16 |
2024-10-16 |
大陸商上海岸闊醫藥科技有限公司 |
化合物及其用途
|
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024201340A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
|
|
WO2024201334A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
|
|
WO2024220532A1
(en)
|
2023-04-18 |
2024-10-24 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
TW202446371A
(zh)
|
2023-04-18 |
2024-12-01 |
美商英塞特公司 |
２－氮雜雙環［２．２．１］庚烷ｋｒａｓ抑制劑
|
|
WO2024231275A1
(en)
|
2023-05-05 |
2024-11-14 |
Astrazeneca Ab |
Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
|
|
WO2024235844A1
(en)
|
2023-05-12 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods of preventing on-target genotoxicity induced by nucleases
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
WO2025051337A1
(en)
|
2023-09-06 |
2025-03-13 |
Afyx Development A/S |
Compositions and methods for treating and preventing oral cancer
|
|
US20250163079A1
(en)
|
2023-11-01 |
2025-05-22 |
Incyte Corporation |
Kras inhibitors
|
|
WO2025122470A1
(en)
|
2023-12-04 |
2025-06-12 |
Genentech, Inc. |
Combination therapies for treatment of breast cancer
|
|
US20250195536A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|